GLP-1 is a promising target for the treatment of depression because impaired neurogenesis ability and the reduction of neuronal differentiation leads to multiple depressive pathological symptoms
In contrast, in people with type 2 diabetes, abnormalities in insulin and glucagon secretion rates persisted during hyperglycemia in the latter case, to the point that hyperglycemia and hyperinsulinemia are insufficient to suppress EGP
See individual product pages for full intended-use details
When it is finally released, its availability must be more strictly controlled than semaglutide to avoid similar life-threatening usage. Dr Marie Spreckley, of the MRC epidemiology unit at the University of Cambridge, said: Higher discontinuation due to adverse events, particularly gastrointestinal symptoms, is a key consideration and may have implications for tolerability and adherence in real-world settings. She added that because the trial lasted only one year, longer-term safety, cardiovascular outcomes and sustained effectiveness remained important unanswered questions
Esserman, L
See more about this vascular-dementia-marijuana connection
